David Fox, MD | University of Michigan | Ann Arbor, MI
Dinesh Khanna, MD | University of Michigan | Ann Arbor, MI
Georgetown University | Washington, DC
University of Michigan | Ann Arbor, MI
Hospital for Special Surgery | New York, NY
University of California Los Angeles | Los Angeles, CA
Boston University | Boston, MA
University of Pittsburgh | Pittsburgh, PA
Medical University of South Carolina | Charleston, SC
University of Texas | Houston, TX
Duke University | Durham, NC
ITN075AI
Active
The main goal of the BRAVOS study is to determine the safety of an investigational study drug, brentuximab vedotin (ADCETRIS®), in diffuse cutaneous systemic sclerosis (dcSSc). Researchers will also assess whether ADCETRIS® has any effect on symptoms associated with dcSSc, and will examine the effect of the ADCETRIS® on the immune system by looking at blood and skin samples.
BRAVOS is a placebo-controlled trial, double-blinded study. Three quarters of participants will receive one of three dosages of brentuximab vedotin (ADCETRIS®) and one quarter will receive placebo.
A total of eight doses of brentuximab vedotin (ADCETRIS®) or placebo will be given by intravenous infusion once every 3 weeks over a 21 week period. Then there will be 4 follow-up visits over the next 6 months. Total study time is 1 year.
Brentuximab vedotin (ADCETRIS®) is approved by the FDA for the treatment of Hodgkin’s and other lymphomas. Researchers think brentuximab vedotin (ADCETRIS®) might also work in dcSSc by attaching to the immune cells that cause dcSSc. Since it has never been tested in patients with dcSSC, brentuximab vedotin (ADCETRIS®) it is considered an experimental drug for this disease.
Brentuximab vedotin (ADCETRIS®) attaches to the CD30 protein on cells and releases a toxin into the cell, causing the cell to die. CD30 is a protein found at low levels on the surface of normal healthy white blood cells. However, the CD30 protein is increased on certain types of cancer cells, and also may be increased on the overactive immune cells involved with inflammation and fibrosis in dcSSc.
You may be eligible to participate in the BRAVOS Study if you: